Telomir Pharmaceuticals TELO
NASDAQ TELO
$1.03 +0.02 (+1.98%)
As of: Oct 21, 2026 · 3:43 PM EDT

Telomir Pharmaceuticals (TELO) Revenue (2024 - 2025)

Updated

Analysis

Telomir Pharmaceuticals (TELO) Revenue (2024 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Eli Lilly 1,138.83 Bn 1,107.41 Bn 19.71 Bn 22.97 Bn
2 Johnson & Johnson 618.88 Bn 537.41 Bn 17.26 Bn 25.31 Bn
3 AbbVie 502.93 Bn 476.04 Bn 12.70 Bn 16.99 Bn
4 Merck 369.61 Bn 323.99 Bn 12.21 Bn 16.61 Bn
5 Novartis Ag 298.70 Bn 262.69 Bn 11.24 Bn 14.41 Bn
6 Astrazeneca 261.35 Bn 235.03 Bn 12.86 Bn 15.38 Bn
7 Amgen 237.59 Bn 192.99 Bn 7.24 Bn 10.05 Bn
8 Gilead Sciences 191.60 Bn 165.79 Bn 6.22 Bn 7.80 Bn
9 Pfizer 170.23 Bn 116.88 Bn 10.94 Bn 15.03 Bn
10 Telomir Pharmaceuticals 62.66 Mn 42.09 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 44,182.00
Jun 30, 2025 22.00
Mar 31, 2025 7,954.00
Sep 30, 2024 15,445.00
Jun 30, 2024 25,493.00
Mar 31, 2024 -4.34 Mn
API Access

Telomir Pharmaceuticals Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=revenue&ticker=TELO&period=max&api_key=YOUR_API_KEY